BiotechTube

Relugolix Combination Therapy

Phase 3Active
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Contraception

Conditions

Contraception

Trial Timeline

Mar 18, 2021 → Feb 1, 2026

NCT ID
NCT04756037

About Relugolix Combination Therapy

Relugolix Combination Therapy is a phase 3 stage product being developed by Sumitomo Pharma for Contraception. The current trial status is active. This product is registered under clinical trial identifier NCT04756037. Target conditions include Contraception.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04756037Phase 3Active

Competing Products

20 competing products in Contraception

See all competitors
ProductCompanyStageHype Score
Injection CyclofemSun PharmaceuticalPhase 1/2
41
Transdermal Contraceptive System + Norgestimate-containing oral contraceptives with EEJohnson & JohnsonPre-clinical
23
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.Johnson & JohnsonPhase 1
33
norelgestromin + ethinyl estradiolJohnson & JohnsonPhase 3
77
norelgestromin + ethinyl estradiol; triphasil.Johnson & JohnsonPhase 3
77
norelgestromin + ethinyl estradiol; mercilonJohnson & JohnsonPhase 3
77
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
33
EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EEJohnson & JohnsonPhase 1
33
Monophasic or triphasic Oral contraceptive tablet + Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EEJohnson & JohnsonPre-clinical
23
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
33
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
33
oral ulipristal acetateMerckPhase 1
33
Etonogestrel contraceptive implantMerckApproved
85
Rifampin 600 MGMerckApproved
85
Long Acting Reversible Contraception (LARC)MerckApproved
85
Etonogestrel contraceptive implantMerckApproved
85
Medroxyprogesterone 17-Acetate + Medroxyprogesterone 17-AcetatePfizerPre-clinical
22
Sayana PressPfizerApproved
84
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mgPfizerPhase 3
76
Depo-Provera Contraceptive Injection - DP150CIPfizerApproved
84

Other Products from Sumitomo Pharma

BlonanserinApproved
85
Mosapride + domperidoneApproved
85
levalbuterol HCl + albuterol SulfateApproved
85
LurasidoneApproved
85
placebo, isotonic ciclesonide, hypotonic ciclesonideApproved
85